Supplement to
The American Journal of Tropical Medicine and Hygiene
COVID-19 has put a halt to much of the health research happening worldwide. It is vital that malaria R&D clinical trials are re-started as soon as possible to ensure that we do not lose valuable time bringing much-needed innovations to market. This session will share perspective from research programmes and funders on how COVID-19 has affected their operations and their planning for re-starting R&D in a safe and effective manner. Holding this symposium will allow stakeholders to share their learnings about re-starting R&D in the face of COVID-19.

SETTING THE STAGE ON MALARIA IN AFRICA AND DISCUSSING THE IMPORTANCE OF NEW TOOLS TO FIGHT MALARIA AND RE-STARTING R&D AND CLINICAL TRIALS AS SOON AS POSSIBLE
Co-Chair: Abdourahmane Diallo
CEO, The RBM Partnership to End Malaria, Geneva, Switzerland

ADDRESSING THE SITUATION ON THE GROUND IN CONDUCTING CLINICAL TRIALS
Co-Chair: Bernards Ogutu
Chief Research Officer, Kenya Medical Research Institute (KEMRI) and Senior Clinical Trialist, Malaria Clinical Trials Alliance of the INDEPTH-Network, Nairobi, Kenya

DISCUSSION OF WHITE PAPER ON INNOVATION AND OVERALL VIEWS ON INNOVATION AND ACCESS ON THE CONTINENT
Catherine Kyobutuni
Executive Director, African Population and Health Research Centre, Nairobi, Kenya

HOW COVID-19 HAS AFFECTED NOVARTIS R&D TIMELINES AND INITIAL LEARNINGS FROM RE-STARTING TRIALS
Caroline Boulton
Global Programme Head, Malaria, Novartis, Basel, Switzerland

HOW COVID-19 HAS AFFECTED THEIR R&D PARTNERSHIPS, HOW THEY HAVE BEEN DOING SCENARIO PLANNING AND HOW FUNDING STREAMS HAVE BEEN AFFECTED
David Reddy
CEO, Medicines for Malaria Venture, Geneva, Switzerland

HOW EDCTP IS HANDLING THE IMPACT OF COVID-19 ON R&D AS A FUNDER
Michael Makanga
CEO, European & Developing Countries Clinical Trials Partnership, The Hague, Netherlands

INFORMING R&D PRIORITIES THROUGH AFRICAN-WIDE DIGITAL PLATFORM FOR INFECTIOUS DISEASES
Lacina Koné
Director General, Smart Africa, Kigali, Rwanda